Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2026 16:05 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ...
February 27, 2026 16:05 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule...
February 13, 2026 08:00 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 12, 2026 08:00 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary; Bryan Jones Named Chief Executive Officer
February 12, 2026 08:00 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Leadership Appointments

Aardvark Therapeutics Announces Leadership Appointments
February 10, 2026 08:00 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

Aardvark Therapeutics announced a Phase 3 HERO trial protocol amendment expanding eligibility for patients with Prader-Willi Syndrome.
December 10, 2025 16:05 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to...
November 25, 2025 16:05 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule...
November 13, 2025 16:05 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Q32025 Earnings
November 11, 2025 16:05 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule...